BBIO logo

BBIO
BridgeBio Pharma Inc

5,368
Mkt Cap
$14.6B
Volume
2M
52W High
$78.59
52W Low
$28.10
PE Ratio
-17.54
BBIO Fundamentals
Price
$72.60
Prev Close
$73.42
Open
$73.79
50D MA
$69.52
Beta
1.32
Avg. Volume
1.79M
EPS (Annual)
-$2.88
P/B
-7.32
Rev/Employee
$303,975.34
Loading...
Loading...
News
all
press releases
BridgeBio Pharma (NASDAQ:BBIO) Now Covered by Morgan Stanley
Morgan Stanley assumed coverage on BridgeBio Pharma in a research report on Tuesday. They issued an "overweight" rating and a $96.00 target price for the company...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 6.5% - Should You Sell?
BridgeBio Pharma (NASDAQ:BBIO) Trading Down 6.5% - Should You Sell...
MarketBeat·22h ago
News Placeholder
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month High - Here's What Happened
BridgeBio Pharma (NASDAQ:BBIO) Hits New 52-Week High - Should You Buy...
MarketBeat·4d ago
News Placeholder
Moody Aldrich Partners LLC Has $3.72 Million Stake in BridgeBio Pharma, Inc. $BBIO
Moody Aldrich Partners LLC decreased its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 25.0% in the 3rd quarter, according to the company in its most recent 13F filing with the...
MarketBeat·5d ago
News Placeholder
Corient Private Wealth LLC Acquires New Holdings in BridgeBio Pharma, Inc. $BBIO
Corient Private Wealth LLC purchased a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the second quarter, according to the company in its most recent disclosure with the...
MarketBeat·9d ago
News Placeholder
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 12-Month High - Here's Why
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 52-Week High - Here's What Happened...
MarketBeat·15d ago
News Placeholder
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the twenty-two ratings firms that are presently covering the stock...
MarketBeat·16d ago
News Placeholder
Assenagon Asset Management S.A. Trims Stake in BridgeBio Pharma, Inc. $BBIO
Assenagon Asset Management S.A. decreased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 26.1% in the 3rd quarter, according to its most recent Form 13F filing with...
MarketBeat·18d ago
News Placeholder
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells 30,011 Shares of Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 30,011 shares of the business's stock in a transaction dated Monday, December 15th. The stock was sold at an average price...
MarketBeat·20d ago
News Placeholder
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 30,011 Shares
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CEO Neil Kumar sold 30,011 shares of BridgeBio Pharma stock in a transaction dated Monday, December 15th. The stock was sold at an average price...
MarketBeat·21d ago
<
1
2
...
>

Latest BBIO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.